Marina Biotech and Hongene Biotechnology Announce License

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marina Biotech and Hongene Biotechnology Announce License Agreement

SHANGHAI, CHINA and BOTHELL, WA--(Marketwired - Sep 28, 2015) - Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases and Hongene Biotechnology Limited announced that they have entered into a License Agreement where Hongene will have exclusive rights to develop, supply and commercialize certain oligonucleotide amidites using Marina's Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina will receive royalties from the sale of CRN-based reagents. Moreover, this Agreement will establish a ready supply of CRN amidites for Marina's therapeutic research and development effots.

"This alliance with Marina is important for Hongene as it exemplifies our strategy to provide a wide variety of high quality nucleosides and nucleotides to those companies and academics advancing cutting edge nucleic acid therapeutics," said Wei Jiang, General Manager of Hongene Biotechnology Ltd. "We have entered into this agreement because we believe Marina's proprietary CRN chemistry provides unique benefits to oligonucleotide constructs, and offers a new research and development tool to the field of nucleic acid based therapeutics. We believe we will be in a position to offer CRN-C and -T amidites by the end of this year and CRN-A and -G amidites early next year."

Conformationally Restricted Nucleotides are patented analogs in which a chemical bridge connects the C2' and C4' carbons of ribose. Ribose, a five-carbon ring-like structure, forms the central component of a nucleotide (comprised of a nucleobase, ribose, and phosphate group). The chemical bridge in the ribose of a CRN locks the ribose in a fixed conformation, which in turn restricts the flexibility of the nucleobase and phosphate group. Substitution of a CRN within an RNA- or DNA-based oligonucleotide has the advantages of increased hybridization affinity and enhanced resistance to nuclease degradation. CRN technology provides a direct means of developing highly potent and specific oligonucleotide-based therapeutics to target messenger RNAs or microRNAs. These targets connect disease pathways that are typically "undruggable" or "difficult to target" with small molecules or monoclonal antibodies, and may be critical in disease areas with significant unmet needs, such as rare diseases, inflammation, metabolic disease, and cancers.

"We are extremely pleased to have entered into this agreement with Hongene," stated J. Michael French, president and chief executive officer of Marina Biotech. "We are focused on the advancement of nucleic acid therapeutics for the treatment of rare diseases and believe that the CRN chemistry is critical to the development of highly active single and double stranded oligonucleotide agents. In particular, CRN-based oligonucleotides will be key to the further development of our preclinical programs in myotonic dystrophy and Duchenne's muscular dystrophy. Hongene will be able to provide Marina and the research community a stable supply of CRN-based oligonucleotides which we hope will, in turn, allow for the further understanding of both disease pathophysiology and the potential for nucleic acid therapeutic intervention."

About Hongene Biotechnology Limited Hongene Biotechnology Limited was established in 1998, and using cutting edge technology, is a dedicated manufacturer in the fields of nucleosides and nucleotides in China. The company supplies only the highest quality products at competitive prices to customers worldwide, and through cooperation with pharmaceutical and biotechnology companies, Hongene Biotechnology Limited is continuously developing new products in this area of science. Our experts are also happy to offer custom syntheses of these and related products essential for your R&D, helping to bring your products to market more efficiently. Through continuous innovation, improvement of manufacturing technologies, the strictest quality control and devoted services, we aim to help our customers achieve their goals more swiftly. Our company motto has always been "Never Knowingly Undersold On Quality." 

About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, MiNA, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina media inquiries: Ryan Ferrell ryan.ferrell@hdmz.com Desk/Mobile: (312) 506-5202 For Marina partnership inquires: J. Michael French President and CEO Marina Biotech, Inc. admin@marinabio.com (425) 892-4322 For Hongene media inquiries: Kan Huang kan.huang@hongene.com China: +86 21.6475.7213 For Hongene partnership inquires: Curtis Cui President Hongene Biotechnology USA, Inc. curtis.cui@hongeneusa.com (919) 371-4711

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 76

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 163

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 160

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 74

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 67

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Alert: Significant Information Regarding V.F. Corporation

Updated Category News Views 188

Understanding the Current Situation at V.F. Corporation V.F. Corporation, commonly referred to as VFC, is in the spotlight as claims are being investigated by legal teams representing investors. If you are among those impacted, it is essential to be well-informed and proactive in understanding your options. Losses Exceeding $50,000 - Know Your Rights If you have suffered...

Continue Reading
ImmunityBio Soars as Anktiva Fuels 700% Revenue Surge

Updated Category News Views 182

The Market's Wild Ride with ImmunityBio Talk about a rollercoaster! ImmunityBio Inc. is strutting its stuff—stock's up over 55% in just the past month! This kinda takes me back to the dot-com bust: exciting ventures, bold promises, and whoosh—away we fly! Honestly, you can’t ignore that hefty 700% revenue jump. And get this— their leading drug, Anktiva, is really...

Continue Reading
Understanding the Class Action Lawsuit Involving Elevance Health

Updated Category News Views 329

Investigating the Class Action Lawsuit Against Elevance Health Investors should be aware of the ongoing class action lawsuit involving Elevance Health, Inc. (NYSE: ELV). This lawsuit has been initiated to address significant concerns regarding false and misleading statements made by the company. The deadline for potential lead plaintiffs to participate is approaching, and...

Continue Reading
Sprott's Financial Performance for Q2 2025 Highlights Growth

Updated Category News Views 189

Sprott Inc. Financial Performance Report Sprott Inc. (NYSE/TSX: SII) has released its financial results for the second quarter of 2025. The company demonstrated significant growth with the total assets under management (AUM) rising to $40 billion by the end of June 2025. This marks a substantial 14% increase from $35.1 billion in the previous quarter and a compelling 27%...

Continue Reading
Analyzing Market Sentiment on Novo Nordisk Stocks

Updated Category News Views 239

Understanding Novo Nordisk's Stock Market Landscape Novo Nordisk has been experiencing notable fluctuations in its stock market sentiment. Recent reports indicate a decline in the company's short percent of float by 9.09%. With approximately 6.36 million shares sold short, this accounts for merely 0.2% of its available trading shares. Furthermore, based on the current...

Continue Reading